The cytochromes P450 (CYPs) are the main enzyme family for metabolism of therapeutic drugs. CYP3A4 is the most active drug metabolizing CYP, and it plays a prominent role in adverse drug-drug ...

This is a preview. Log in through your library . Abstract Cobalt has complex actions on the metabolism of heme in the liver. In this organ the metal potently induces heme oxygenase (EC 1.14.99.3), and ...

Enzyme inhibitors play a pivotal role in pharmaceutical and nutraceutical industries. The primary understanding of the action of inhibitors helps pharmacologists during the design process for ...

Identification of a small-molecule inhibitor of Stat5a/b through structure-based screen for therapy development for prostate cancer. Background: Abiraterone is a novel inhibitor of the steroidogenic ...

This is a preview. Log in through your library . Abstract The effects of various inhibitors of protein and nucleic acid synthesis on the development of invertase activity and increased nucleolar ...

Few studies have directly compared the renoprotective effects of angiotensin II–receptor blockers and angiotensin-converting–enzyme (ACE) inhibitors in persons with type 2 diabetes. In this ...

Characteristics of newly diagnosed stage IV colorectal cancer (CRC) in veterans over a 10-year period. This is an ASCO Meeting Abstract from the 2014 ASCO Annual Meeting I. This abstract does not ...

STC-15 is the first molecule specifically targeting METTL3 to enter clinical development 8 August 2023, Cambridge, UK: STORM Therapeutics Ltd. (STORM), a clinical stage biotechnology company focused ...

A novel nanoparticle system combines sonodynamic therapy and ferroptosis to effectively target hepatocellular carcinoma and ...

STC-15 is the first molecule specifically targeting METTL3 to enter clinical development Oliver Rausch, Chief Scientific Officer of STORM Therapeutics and joint senior author of the study, said, "We ...